Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART)
|
|
- Gwenda Knight
- 5 years ago
- Views:
Transcription
1 376 Neurology, University Clinic Essen, Hufelandstrasse 55, Essen, Germany M Maschke O Kastrup A Hufnagel Dermatology S Esser U Hengge Internal Medicine B Ross Correspondence to: Dr Matthias Maschke matthias.maschke@uni-essen.de Received 13 September 1999 and in final form 21 March 2000 Accepted 12 April 2000 Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART) Matthias Maschke, Oliver Kastrup, Stefan Esser, Birgit Ross, Ulrich Hengge, Andreas Hufnagel Abstract Objective To determine the change of incidence and prevalence of neurological disorders caused by the human immunodeficiency virus (HIV) and opportunistic infections in HIV positive patients under treatment since the introduction of highly active antiretroviral therapy (HAART). Methods The data of all HIV infected patients were retrospectively analysed, who were examined in the HIV outpatients clinic of the neurological department of the University Clinic Essen between 1995 and 1998 (n=563, total number of visits- =735). Data from identified patients were divided into two groups according to the time of examination from 1995 to 1996 (334 visits) and from 1997 to 1998 (401 visits). The incidence and prevalence of neurological disorders were statistically compared between both time intervals. Results Significantly more patients received HAART in (p<0.001) and mean CD4+ cell count was significantly higher in (p<0.001). The prevalence of HIV associated dementia and HIV associated polyneuropathy were significantly lower in (both: p=0.02) and the incidence of toxoplasma encephalitis decreased from 5.7% in to 2.2% in (p=0.015). Based on the small number of patients significant changes in HIV associated myopathy, progressive multifocal leukoencephalopathy, cryptoccocal meningitis, and cytomegalovirusencephalitis could not be detected. Conclusion The prevalence of the most frequent HIV associated neurological disorders and incidence of toxoplasma encephalitis decreased since the introduction of HAART. This may be due to the improvement of immunostatus by HAART as demonstrated by the higher CD4+ cell count in the later time interval. Direct antiretroviral evects within the nervous system may be considered causative as well. The prevalence and incidence of HIV associated neurological disorders and opportunistic CNS infections decreased after introduction of HAART. (J Neurol Neurosurg Psychiatry 2000;69: ) Keywords: HIV; highly active antiretroviral therapy; HIV associated dementia; toxoplasma encephalitis; incidence; prevalence J Neurol Neurosurg Psychiatry 2000;69: Infection with HIV is often complicated by neurological disorders in the later phases of the disease. In the time before antiretroviral combination therapy in the form of the so called highly active antiretroviral therapy (HAART) was available, neurological complications were the initial manifestation of the acquired immunodeficiency syndrome (AIDS) in 7%-20%. It is reported that 39%-70% of all patients with AIDS or symptomatic HIV infection developed neurological disorders. 1 Recently, two studies reported a decrease in the incidence of opportunistic CNS infections such as toxoplasma encephalitis after the initiation of HAART. 2 3 However, whether HAART leads to a reduction in incidence and prevalence of HIV associated dementia and HIV associated polyneuropathy remains unclear. This study investigated the incidence and prevalence of HIV related disorders before and after introduction of HAART between the years 1995 and Patients and methods All patients with known HIV infection, who were examined between 1995 and 1998 in the neurological department of the University Clinic of Essen, were retrospectively identified and included in the analysis. The total number of identified patients was 563 with a total number of 735 visits during the whole time period. According to the time of examination the data of the study population were divided into the time interval from (334 visits) and from (401 visits); 80.3% (452) of patients were seen only once in the whole time period, whereas 17.7% (111) were seen more than once. Incidence data from patients who were seen more than once were counted only in the year of diagnosis. By contrast, prevalence data (for example, HIV associated dementia, distal symmetric polyneuropathy, and myopathy) were counted for each visit, but only once for each year. The referral pattern of the patients did not change across the years. Basic characteristics (sex, age, disease duration, CD4+ cell count, antiretroviral therapy) were obtained from chart records at the neurological department and at the two referring departments of the same institution (department of dermatology, department of internal medicine). Basic characteristics are summarised in table 1. Briefly, mean CD4+ cell counts were significantly higher in Significantly more patients received
2 Incidence and prevalence of neurological disorders associated with HIV 377 Table 1 Basic characteristics of patient populations in and (n=334) (n=401) p Value Sex: NS* Male 81.1% 84.5% Female 18.9% 15.5% iv Drug abuse 10.2% 15.9% NS* Mean age (SD) 38.6 (9.5) 40.7 (10.6) Mean disease duration/y (SD) 5.2 (3.5) 5.0 (3.7) NS Mean CD4+ cell count/µl (SD) 214 (212) 335 (267) <0.001 Proportion of patients under HAART 34.2% 79.3% <0.001* HAART=Highly active antiretroviral therapy; iv=intravenous. *χ 2 test; t test. Table 2 HAART in In , the antiretroviral therapy consisted mainly of a combination of two nucleoside reverse transcriptase inhibitors (zidovudine (AZT)+lamivudine (3TC) and AZT+zalcitabine (ddc), AZT+didanosine (ddi), ddi+3tc). After the introduction of protease inhibitors, and thus introduction of HAART, in 1996, therapy consisted of a combination of one protease inhibitor with two reverse transcriptase inhibitors (AZT+3TC+saquinavir (SQV) or indinavir, stavudine (d4t)+ddi+sqv or indinavir), a combination which was not diverent from the HAART used in The use of prophylactic antibiotics against toxoplasma encephalitis did not change from 1995 to Every patient with a CD4+ cell count below 250/µl received cotrimoxazole (400 mg sulfamethoxazole+80 mg trimethoprim once a day). In the case of intolerance, patients received pyrimethamine (25 mg twice daily+15 mg folinic acid twice a week) in combination with pentamidine inhalations (200 mg every 4th week). HIV associated dementia was diagnosed according to the guidelines of the AIDS Task Force of the American Academy of Neurology 4 and in the absence of other causes of dementia (toxic and metabolic encephalopathy, progressive multifocal leukoencephalopathy, other opportunistic CNS infections). The diagnosis of HIV associated distal symmetric sensory polyneuropathy was established in the case of distal symmetric numbness or paraesthesias, reduced or absent ankle reflexes, loss or marked impairment of vibration sense, and typical pathological sensory and/or motor nerve conduction studies. Drug induced polyneuropathy was considered in patients receiving didanosine (ddi), zalcitabine (ddc), and stavudine (d4t) and improvement of symptoms after reduction or termination of these drugs. The diagnosis of HIV associated myopathy was made if proximal myalgia, increased creatine kinase, or myopathic changes on EMG were present and the patients were not on azidothymidine (AZT) at the time Basic characteristics of patients with HIV associated dementia Number of patients Prevalence 17.1% 11.2% Mean CD4+cell count/µl (SD) 178 (245) 271 (279) Mean disease duration/y (SD) 6.9 (3.1) 6.2 (3.7) Proportion of patients under HAART 25.5% 95.0% iv Drug misuse 33.3% 26.7% HAART=Highly active antiretroviral therapy; iv=intravenous. of diagnosis. Toxoplasma encephalitis was suspected in patients with focal signs and symptoms, multifocal enhancing mass lesions in MRI or CT, positive toxoplasma antibodies, and improvement of symptoms after initiation of unidirectional antitoxoplasmosis therapy (therapy with pyrimethamine and sulfadiazine or clindamycine). Cryptococcal meningitis was considered in the presence of typical symptoms and detection of cryptococcal antigen or direct identification of cryptoccal organisms in the CSF. Progressive multifocal leukoencephalopathy (PML) was diagnosed in patients with progressive focal signs and symptoms, decline in cognitive function, multifocal nonenhancing white matter lesions on MRI, positive JC virus polymerase chain reaction in CSF, or positive necropsy findings. Cytomegalovirus (CMV) encephalitis was assumed in the presence of focal signs and symptoms, positive CMV-DNA in plasma and CSF, and nonspecific pathological MR findings such as ventriculomegaly, periventricular enhancement, or cortical and subcortical inflammation and positive necropsy. Primary cerebral lymphoma was diagnosed in patients with unifocal enhancing mass lesions shown by MRI and positive findings on brain biopsy. In a statistical analysis, the 2 year incidences of opportunistic infections were compared between both time intervals ( v ). For HIV associated dementia, myopathy, and polyneuropathy the 2 year prevalence was calculated and compared between both time intervals by χ 2 tests. Numerical parameters were compared by means of the t test. p Values<0.05 were considered significant. Results HIV ASSOCIATED DEMENTIA The prevalence of HIV associated dementia decreased markedly from to (table 2). In HIV associated dementia was diagnosed in 57 patients (17.1% of all patients in this interval), whereas in the diagnosis was established in 45 patients (11.2%). This diverence was significant (p=0.022). Patients with the diagnosis of HIV associated dementia had lower CD4+ cell counts than patients without disease, although this trend was non-significant (table 2). In significantly more patients with HIV associated dementia received HAART in comparison with the remaining subjects (95% v 77%, p=0.009). By contrast, the proportion of patients receiving HAART was not significantly diverent between patients with HIV associated dementia and others in (25.5% v 35.9%, p=0.151). The disease duration of patients with HIV associated dementia was significantly longer compared with patients without dementia both in and (p<0.001 and p=0.018). The proportion of patients with HIV associated dementia, who reported intravenous drug misuse, was higher in comparison with patients without dementia (1995 6: 33.3% v 12.5%; : 26.7% v 8.1%).
3 378 Maschke, Kastrup, Esser, et al HIV ASSOCIATED DISTAL SYMMETRIC SENSORY POLYNEUROPATHY The prevalence of HIV associated distal symmetric sensory polyneuropathy (DSP) showed a decline from to In DSP was found in 142 patients (42.5%) compared with the lower frequency of 138 patients (34.4%) in (table 3). The diverence between both intervals was significant (p=0.022). Patients with DSP had a significantly lower CD4+ cell count (p<0.001) and a significantly longer disease duration (p=0.005) in compared with patients without DSP, whereas there were no significant diverences between patients with and without DSP in (p=0.2 for CD4+ cell count and p=0.09 for disease duration, table 3). Significantly more patients with DSP received HAART compared with patients without DSP in (90.3% v 73.2%, p>0.001). By contrast, there was no significant diverence in the proportion of patients with DSP and HAART and patients without DSP and HAART in (38.6% v 30.9%, p=0.15). Suspected drug induced polyneuropathy as the cause of distal symmetric polyneuropathy was found in 43 patients in (31.2% of all patients with DSP). In drug induced DSP was diagnosed in 29 patients (20.4% of all patients with DSP). The proportion of patients with drug induced DSP was significantly higher in compared with the other time interval (p=0.04). Table 3 Basic characteristics of patients with HIV associated distal symmetric sensory polyneuropathy Number of patients Prevalence 42.5% 34.4% Mean CD4+ cell count/µl (SD) 194 (198) 260 (230) Mean disease duration/y (SD) 5.6 (3.6) 5.7 (3.6) Proportion of patients under HAART 38.6% 90.3 Proportion of drug induced DSP 20.4% 31.2% HAART=Highly active antiretroviral therapy; DSP=distal symmetric sensory polyneuropathy. Table 4 Basic characteristics of patients with toxoplasma encephalitis Number of patients 19 9 Incidence 5.7% 2.2% Mean CD4+cell count/µl (SD) 87 (94) 117 (90) Mean disease duration/y (SD) 4.8 (3.0) 5.2 (3.7) Proportion of patients under HAART 25% 67% HAART=highly active antiretroviral therapy. Table 5 Frequencies of other opportunistic CNS infections than toxoplasma encephalitis and frequency of primary CNS lymphoma (n(%)) (n(%)) Cryptococal meningitis 3 (0.9) 1 (0.2) Progressive multifocal leukoencephalopathy 2 (0.6) 2 (0.5) CMV encephalitis 4 (1.2) 6 (1.5) Tuberculosis meningitis 3 (0.9) 3 (0.7) Primary CNS lymphoma 2 (0.5) 1 (0.2) CMV=cytomegalovirus. HIV ASSOCIATED MYOPATHY The overall prevalence of HIV associated myopathy was low in our study population. In only eight patients (2.4%) showed signs and symptoms of HIV associated myopathy, whereas HIV associated myopathy was diagnosed in six patients (1.5%) in This small diverence was not significant. Basic characteristics of these patients are not presented due to the low prevalence and lack of change between both intervals. TOXOPLASMA ENCEPHALITIS Toxoplasma encephalitis was found in 19 patients (5.7%) in , whereas only nine patients developed toxoplasma encephalitis in (2.2%) reflecting a significant decrease in the incidence of toxoplasma encephalitis from to (p=0.015, table 4). The disease duration was not significantly diverent in patients with toxoplasma encephalitis compared with the remaining patients (both intervals p>0.2), but CD4+ cell counts were significantly lower in both (p=0.01) and (p=0.03). There was no diverence in the proportion of patients with toxoplasma encephalitis who received HAART compared with other patients (both intervals p>0.2). PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, CYTOMEGALOVIRUS ENCEPHALITIS, CRYPTOCOCCAL MENINGITS, AND PRIMARY CNS LYMPHOMA The incidence of opportunistic CNS infections other than toxoplasma encephalitis was very low in both intervals and there was no significant change between and Primary CNS lymphoma was also found only in a small proportion of patients. Exact frequencies are summarised in table 5. Discussion Opportunistic CNS infection and HIV associated neurological disorders such as HIV associated dementia and HIV associated distal symmetric polyneuropathy often complicate later stages of HIV disease and occur in up to 40%-60% of all patients with AIDS during their lifetime. 5 Recently, Brodt et al 2 and Michaels et al 3 reported a decline in incidence and prevalence of opportunistic CNS infections, which may be related to the introduction and widespread use of the highly active antiretroviral therapy (HAART) in western countries since Whether HAART also has an impact on frequency of HIV associated disorders such as HIV associated dementia or HIV associated polyneuropathy remains unclear. The present study focuses on the changes in incidence of opportunistic CNS infections and prevalence of HIV associated disorders (dementia, polyneuropathy, myopathy) since the introduction of HAART. In our study population, the prevalence of HIV associated dementia (HAD) showed a significant decrease from to This finding is underlined by the results of the Multicentre AIDS Cohort Study (MACS), which recently also reported a trend towards a decreased rate of HAD comparing incidence rates in with and In that cohort, incidence rates were 17.4/1000 person-years in /1000 personyears in respectively. However,
4 Incidence and prevalence of neurological disorders associated with HIV 379 prevalence rates were not reported. In the present study, the higher proportion of patients in compared with , who received HAART, may indicate that the decline of HAD may be due to therapy. However, this has to be proved in prospective studies. By contrast, an Australian study found a relative increase of HIV associated dementia as the initial AIDS defining illness after the introduction of HAART (4.4% from , 6.0% in 1996, and 6.5% in 1997). 7 It has to be taken into account that data about the initial AIDS defining illness do not have to correspond closely with the prevalence data. Moreover, there may beadiverence in epidemiological data between western countries due to the diverent proportion of patients with intravenous drug misuse, which may act as a predisposing factor for the development of HIV associated dementia. In the present study, there was a significantly higher proportion of patients with disease who were on HAART in comparison with patients without disease in This should not be interpreted as an indication that HAART is associated with HAD. There may be two explanations for this fact. Firstly, patients with HAD or DSP have more advanced stages of HIV infection, and thus are more likely to be on HAART. Secondly, patients with HAD or DSP are more prone to have disease than patients without any symptoms and thus are more likely to consider taking drugs and consult an HIV specialist regularly. Whether HAART leads to a direct inhibition of HIV within the CNS or acts via improvement of the general immunostatus is a matter of debate. HAART mostly includes at least one protease inhibitor, substances that have only poor CSF penetration. Despite this shortcoming, inhibitors of the reverse transcriptase namely, azidothymidine (AZT), dideoxyinosine (ddi), and stavudine (d4t) show suycient CSF/plasma ratios and a preliminary study has demonstrated that suppression of HIV RNA within the CSF can occur with indinavir 8 or with a combination therapy. 9 In the present study, higher CD4+ cell counts in compared with reflect an improvement in the general immunostatus of patients. Thus, the decrease in the prevalence of HAD may be explained by direct inhibition of HIV within the brain as well as by improvement of immunological indices by HAART. Moreover, HAART may lead to suppression of inflammatory neurotoxins within the brain. This assumption is supported by a study which investigated changes in inflammatory neurotoxins due to HAART in patients with HAD. 9 That study showed a significant decrease in levels of tumour necrosis factor-α, quinolinic acid, and nitric oxide in plasma and CSF. Whether HAART is only preventive or may also reverse cognitive symptoms was examined by a recent study, which noted an improvement of psychomotor speed performance in HIV infected patients who received HAART. 10 Another remarkable result was the higher mean CD4+ cell count of patients with HAD in the time interval from with a mean CD4 cell count of 271/µl in our study. This was confirmed by a recently published study by Sacktor et al. 6 They reported that the CD4+ cell count nearest to the time of diagnosis of HAD was>200 in only 29% of patients with HAD from , but was>200 in 63% of the HAD cases from This indicates that HAD nowadays may also occur in patients with relatively normal CD4+ cell counts. Furthermore, in the present study there was a higher proportion of patients with intravenous drug misuse in the group of patients with HAD compared with the general population. This finding was also made by others, 11 but among AIDS cases reported to the CDC, dementia has been found with similar frequency among all risk groups in the United States. 12 Thus, it remains unclear whether intravenous drug misuse is a risk factor for the development of HAD. However, there is increasing evidence that drugs such as cocaine enhance HIV invasion of the brain by an increase in permeability of the blood-brain barrier. 13 Another important result of the present study was the significant decline in the prevalence of HIV associated distal symmetric polyneuropathy (DSP) in the time interval from The prevalence rate (34.4%) during that time interval was lower than prevalence rates reported by studies in the time before the introduction of HAART. 14 The higher proportion of patients who received HAART in the time interval from compared to the time interval from suggested that the decline in prevalence may be related to HAART. HAART leads to an improvement in CD4+ cell counts, reflected by a higher mean CD4+ cell count in patients of the time interval from Interestingly, a recent study showed a predictive value of CD4+ cell counts for the development of DSP. 15 In that study, patients with CD4+ cell counts below 750/mm 3 had a 1.4 fold greater risk of DSP than those with CD4+ cell counts above 750/mm 3. Whether HAART also improves symptoms in patients with DSP has yet to be determined. However, case reports suggested that HAART may be evective in treatment of DSP, which hypothetically may be due to suppression of macrophage activation and neurotoxin production in the peripheral nerve. 16 Another interesting point in the present study was the increase in the prevalence of toxic neuropathies in the time interval from This might be associated with a frequent use of possible neurotoxic antiretroviral drugs such as stavudine (d4t) and didanosine (ddi), which are not uncommonly used in combination with a protease inhibitor. However, these changes in prevalence should be regarded cautiously in the light of the retrospective character of the study. The third main point of the present study is the significant decrease in the incidence of toxoplasma encephalitis in the time interval from This result is in keeping with the decline of toxoplasma encephalitis in the past years reported by Brodt et al 2, Michaels et al, 3 and Sacktor et al. 6 By contrast with patients with HAD and DSP, patients with toxoplasma encephalitis showed a low CD4+ cell count
5 380 Maschke, Kastrup, Esser, et al both in the time interval from and from This finding indicates that toxoplasma encephalitis commonly occurs in patients with advanced immunosuppression, a fact which has already been found by others in the time period before the introduction of HAART This decrease in the incidence may be related to HAART, which leads to a smaller proportion of patients with advanced immunosuppression indicated by the higher mean CD4+ cell count in our patient population in the time interval from The lack of change in cryptococcal meningitis, cytomegalovirus encephalitis, progressive multifocal leukoencephalopathy (PML), and primary CNS lymphoma as well as HIV associated myopathy is probably explained by the low number of patients with these conditions in both the time interval from and from However, others reported a decline in all cytomegalovirus infections after introduction of HAART. 2 3 Whether HAART has an impact on development of PML remains to be investigated, but two recent studies showed an improvement in prognosis of PML due to HAART. In the Multicenter AIDS Cohort Study, there was a trend toward a decreased rate of cryptococcal meningitis as well as primary CNS lymphoma after introduction of HAART. 6 In conclusion, the present study showed a significant decrease in the prevalence of the two most common HIV associated neurological disorders, HIV associated dementia and HIV associated distal symmetric sensory polyneuropathy, after the introduction of highly active antiretroviral therapy (HAART). Moreover, HAD and DSP seems to occur nowadays at a higher range of CD4+ cell counts. The incidence of toxoplasma encephalitis also showed a decline after introduction of HAART, but still tended to occur regularly in patients with advanced immunosuppression. Further prospective studies are necessary to confirm these results and to identify which combination of antiretroviral agents inhibits best the development of HIV related neurological disorders. 1 Janssen RS. Epidemiology and neuroepidemiology of human immunodeficiency virus infection. In: Berger JR, Levy RM, eds. AIDS and the nervous system, 2nd ed. Philadelphia: Lippincott-Raven 1997: Brodt HR, Kamps BS, Gute P, et al. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997;11: Michaels J, and the Adult Spectrum of Disease Cohort. Opportunistic incidence rates from the Tulane/adult spectrum of disease cohort, Fifth conference on retroviruses and opportunistic infections. Chicago, 1998; Janssen RS, Cornblath DR, Epstein LG, et al. Human immunodeficiency virus (HIV) infection and the nervous system: report from the American Academy of Neurology AIDS Task Force. Neurology 1989;39: Bendok B, Berger JR, Levy RM. Acquired immunodeficiency syndrome and the nervous system: fifteen years of progress. In: Berger JR, Levy RM, eds. AIDS and the nervous system. 2nd ed. Philadelphia: Lippincott-Raven, 1997: Sacktor N, Lyles RH, McFarlane G, et al, and the multicenter AIDS cohort study. HIV-1 related neurological disease incidence change in the era of highly active antiretroviral therapy. Neurology 1999;52:A Dore GJ, Correll PK, Li Y, et al. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999;12: Collier AC, Marra C, Coombs RW,et al. Cerebrospinal fluid indinavir and HIV RNA levels in patients on chronic indinavir therapy. In: Program and abstracts of the Infectious Disease Society of America 35th annual meeting. San Francisco, CA: 1997;September 13 16:75. 9 Gendelman HE, Zheng J, Coulter CL, et al. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-asscociated dementia. J Infect Dis 1998;178: Sacktor N, Lyles RH, Skolasky RL, et al, for the multicenter AIDS cohort study (MACS). Combination antiretroviral therapy improves psychomotor speed performance in HIVseropositive homosexual men. Neurology 1999;52: Schwartlander B, Horsburgh CR Jr, Hamouda O, et al. Changes in the spectrum of AIDS-defining conditions and decrease in CD4+ lymphocyte counts at AIDS manifestation in Germany from AIDS 1992;6: Janssen RS, Nwanyanwu OC, Selik RM, et al. Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 1992;42: Zhang L, Looney D, Taub D, et al. Cocaine opens the blood-brain barrier to HIV-1 invasion. J Neurovirol 1998;4: So YT, Holtzman DM, Abrams DI, et al. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. Arch Neurol 1988;45: Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999;52: Markus R, Brew BJ. HIV-1 peripheral neuropathy and combination antiretroviral therapy. Lancet 1998;352: Dannemann B, McCutchan JA, Israelski D, et al, for the California Collaborative Treatment Group. Treatment of toxoplasma encephalitis in patients with AIDS, a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med 1992; 116: Girard PM, Landman R, Gaudebout C, et al, for the PRIO Study Group. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med 1993;328: Levy RM, Janssen RS, Bush TJ, et al. Neuroepidemiology of acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr Hum Retrovirol 1988;1: Albrecht H, HoVmann C, Degen O, et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 1998;12: CliVord DB, Yiannoutsos C, Glicksman M, et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 1999;52:623 5.
May He Rest in Peace
May He Rest in Peace Neurologic Complications of AIDS Medical Knowledge Fiesta 2012 Paul K. King MD pkingmd@yahoo.com Objectives definition of HIV/AIDS what are the neurologic complications of AIDS how
More informationThe Neurology of HIV Infection. Carolyn Barley Britton, MD, MS Associate Professor of Clinical Neurology Columbia University
The Neurology of HIV Infection Carolyn Barley Britton, MD, MS Associate Professor of Clinical Neurology Columbia University HIV/AIDS Epidemiology World-wide pandemic, 40 million affected U.S.- Disproportionate
More informationImprovement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors
(2000) 6, 84 ± 88 ã 2000, Inc. www.jneurovirol.com Short Communication Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors Ned Charlton Sacktor*,1, Richard
More informationOUTCOME CODES FOR MACS STATUS FORM
OUTCOME CODES FOR MACS STATUS FORM CODE CDC-DEFINED AIDS DIAGNOSES (Section C) 01 Kaposi's sarcoma 02 Pneumocystis carinii pneumonia 03 Toxoplasmosis (at a site other than or in addition to liver, spleen,
More informationNeuroradiology of AIDS
Neuroradiology of AIDS Frank Minja,, HMS IV Gillian Lieberman MD September 2002 AIDS 90% of HIV patients have CNS involvement 1 10% of AIDS patients present first with neurological symptoms 2 73-80% of
More informationUpdate on Neurologic Complications in Persons With HIV Infection: 2017
Update on Neurologic Complications in Persons With HIV Infection: 2017 FORMATTED: MM/DD/YY Chicago, Illinois: May 10, 2017 Dennis Kolson, MD, PhD Professor of Neurology University of Pennsylvania Philadelphia,
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More informationOpportunistic infections in the era of cart, still a problem in resource-limited settings
Opportunistic infections in the era of cart, still a problem in resource-limited settings Cristiana Oprea Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania Assessment
More informationCryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease
Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol
More informationCerebral Toxoplasmosis in HIV-Infected Patients. Ahmed Saad,MD,FACP
Cerebral Toxoplasmosis in HIV-Infected Patients Ahmed Saad,MD,FACP Introduction Toxoplasmosis: Caused by the intracellular protozoan, Toxoplasma gondii. Immunocompetent persons with primary infection
More informationGood Neurocognitive Performance Measured by the International HIV Dementia Scale in Early HIV-1 Infection
BRIEF REPORT: CLINICAL SCIENCE Good Neurocognitive Performance Measured by the International HIV Dementia Scale in Early HIV-1 Infection Gustavo D. Lopardo, MD,* Emiliano Bissio, MD,* María del C. Iannella,*
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More informationCentral Nervous System Immune Reconstitution Disease: Pathology
Central Nervous System Immune Reconstitution Disease: Pathology F.Gray, H.Adle-Biassette, F.Héran, G. Pialoux, A.Moulignier, APHP Hôpital Lariboisière Université Paris VII Introduction of HAART, which
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationHIV Dementia Scale and Psychomotor Slowing The Best Methods in Screening for Neuro-AIDS
HIV Dementia Scale and Psychomotor Slowing The Best Methods in Screening for Neuro-AIDS Hans-Jürgen von Giesen, M.D. Bernhard A. Haslinger, M.D. Simone Rohe Hubertus Köller, M.D. Gabriele Arendt, M.D.
More informationA clinical study of neurological manifestations in HIV positive patients in a tertiary care hospital of Telangana, India
Original Research Article A clinical study of neurological manifestations in HIV positive patients in a tertiary care hospital of Telangana, India Kamera Sateesh Kumar 1*, Veena Narisetty 2, P. Chandra
More informationSustained cognitive decline in HIV infection: relationship to CD4+ cell count, plasma viremia and p24 antigenemia
Short Communication Journal of NeuroVirology (1998) 4, 95 ± 99 ã 1998 Journal of NeuroVirology, Inc. http://www.jneurovirol.com : relationship to CD4+ cell count, plasma viremia and p24 antigenemia Gerald
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationClinical Manifestations of HIV
HIV Symptoms Diane Havlir, MD Professor of Medicine and Chief, HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 2, 2013 1 Clinical Manifestations of HIV! Result from
More informationNatural History of Untreated HIV-1 Infection
Opportunistic infections Dr. Guido van den Berk December 2009 HIV [e] EDUCATION Natural History of Untreated HIV-1 Infection 1000 + CD4 Cells 800 600 400 Constitutional Symptoms Early Opportunistic Infections
More informationOverview on Opportunistic Infections of the Central Nervous System
Second HIV Infection and the Central Nervous System: Developed and Resource-Limited Settings Venice, Italy April 14 16, 2007 Overview on Opportunistic Infections of the Central Nervous System Adriana Ammassari
More informationA Child with Cross Eye. Nia Kurniati
A Child with Cross Eye Nia Kurniati Background When dealing with new case with potential social problem, complication related to ARV treatment may pose difficulties Restricted resource to address potential
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationLahey Clinic Internal Medicine Residency Program: Curriculum for Infectious Disease
Lahey Clinic Internal Medicine Residency Program: Curriculum for Infectious Disease Faculty representative: Eva Piessens, MD, MPH Resident representative: Karen Ganz, MD Revision date: February 1, 2006
More informationTo interrupt or not to interrupt Are we SMART enough?
SMART To interrupt or not to interrupt Are we SMART enough? highly active antiretroviral therapy 5 1996 1997 10 25 43 45 35 metabolism 50 copies/ml lipodystrophy [fat redistribution syndrome] lactic acidosis
More informationA Profile of HIV patients with CNS manifestations: A descriptive study
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 3 Number 12 (2014) pp. 901-906 http://www.ijcmas.com Original Research Article A Profile of HIV patients with CNS
More informationNEUROCOGNITIVE IMPAIRMENT IN A NEWLY DIAGNOSED HIV POSITIVE PATIENT WITH ADVANCED DISEASE
Vol XIV, Number 3, September 2010 Pages 224-230 Copyright reserved 2010 THERAPEUTICAL PRACTICE NEUROCOGNITIVE IMPAIRMENT IN A NEWLY DIAGNOSED HIV POSITIVE PATIENT WITH ADVANCED DISEASE Adriana Hristea
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More information227 28, 2010 MIDTERM EXAMINATION KEY
Epidemiology 227 April 28, 2010 MIDTERM EXAMINATION KEY Select the best answer for the multiple choice questions. There are 64 questions and 9 pages on the examination. Each question will count one point.
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationDisclosure. Learner Objectives. Congenital Infections. Question. Main Categories 4/26/2016
Communicating Communicability: Imaging of CNS Infections Aaron P. Kamer, MD Assistant Professor of Clinical Radiology Neuroradiology Section April 26, 2016 Disclosure Within the past 12 months: I have
More informationCOGNITIVE DYSFUNCTION AMONG HIV-POSITIVE PATIENTS ATTENDING CCC AT KENYATTA NATIONAL HOSPITAL
COGNITIVE DYSFUNCTION AMONG HIV-POSITIVE PATIENTS ATTENDING CCC AT KENYATTA NATIONAL HOSPITAL Principal Investigator Dr. Zaheer Bagha Supervisors Prof. E. Amayo Prof. A. M. Adam Dr. J. O. Mecha INTRODUCTION
More informationAntiviral Chemotherapy
Viruses are intimate intracellular parasites and their destruction may cause destruction of infected cells. Many virus infections were considered to be self-limited. Most of the damage to cells in virus
More informationReasons why we will never forget. Andrea Antinori INMI L. Spallanzani IRCCS, Roma
Reasons why we will never forget Andrea Antinori INMI L. Spallanzani IRCCS, Roma SMRs according to time spent with CD4 count >500/mm3 after cart initiation in MSM 80,642 HIV-infected individuals eligible
More informationHIV in Obstetrics and Gynecology
FAST FACTS HIV in Obstetrics and Gynecology Indispensable Guides to Clinical by J Richard Smith, Naomi Low-Beer and Bruce A Barron Practice HIV infection 7 Managing infected women 13 Preconceptual care
More informationAIDS at 30 Epidemiology and Clinical Epidemiology and Management MID 37
AIDS at 30 Epidemiology and Clinical Management Blood HIV Transmission transfusion injection drug use Sexual Intercourse heterosexual male to male Perinatal intrapartum breast feeding Adults and children
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationCentral Nervous System and HIV/AIDS
UPDATE ARTICLE Central Nervous System and HIV/AIDS Naveet Wig*, J P Wali** Introduction HIV-infection and particularly its late stage of severe immunodeficiency (AIDS) render the nervous system susceptible
More informationAIDS at 25. Epidemiology and Clinical Management MID 37
AIDS at 25 Epidemiology and Clinical Management Blood HIV Transmission transfusion injection drug use Sexual Intercourse heterosexual male to male Perinatal intrapartum breast feeding Regional HIV and
More informationMortality Rates Among People With HIV, Long on the Wane, Continue to Drop HIV Medicine Feb 2013
John F. White III, MD, MBA, FLMI VP and Medical Director American National Insurance Company 1 Mortality Rates Among People With HIV, Long on the Wane, Continue to Drop HIV Medicine Feb 2013 2 1 3 My Opinions
More informationPNEUMOCYSTIS PNEUMONIA AMONG HIV PATIENTS IN MALAYSIA
PNEUMOCYSTIS PNEUMONIA AMONG HIV PATIENTS IN MALAYSIA H Siti Asma 1, Mahiran Mustafa 5, Shukri Abdullah 2, AR Zaidah 1, AR Nurhaslindawati 4, A Sarimah 3, YY Chan 1 and M Ravichandran 1 1 Department of
More informationImmunodeficiencies HIV/AIDS
Immunodeficiencies HIV/AIDS Immunodeficiencies Due to impaired function of one or more components of the immune or inflammatory responses. Problem may be with: B cells T cells phagocytes or complement
More informationHIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego
Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive
More informationHuman Immunodeficiency Virus. Acquired Immune Deficiency Syndrome AIDS
Human Immunodeficiency Virus Acquired Immune Deficiency Syndrome AIDS Sudden outbreak in USA of opportunistic infections and cancers in young men in 1981 Pneumocystis carinii pneumonia (PCP), Kaposi s
More informationCONCISE COMMUNICATION
740 CONCISE COMMUNICATION Antiretroviral Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Protease from Paired Cerebrospinal Fluid and Plasma Samples Giulietta Venturi,
More informationJMSCR Vol 04 Issue 12 Page December 2016
www.jmscr.igmpublication.org Impact Factor 5.244 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v4i12.128 Neurological Manifestations in the
More information2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?
Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is
More informationHydroxyurea with ddi or ddi/d4t: a novel approach to HIV therapy
National AIDS Treatment Advocacy Project Hydroxyurea with ddi or ddi/d4t: a novel approach to HIV therapy Results from several hydroxyurea (ddi+hydroxyurea) studies were reported at Vancouver (July `96)
More informationHigher Risk of Hyperglycemia in HIV-Infected Patients Treated with Didanosine Plus Tenofovir
6131_06_p333-337 4/5/06 10:28 AM Page 333 AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 22, Number 4, 2006, pp. 333 337 Mary Ann Liebert, Inc. Higher Risk of Hyperglycemia in HIV-Infected Patients Treated
More informationReassessment: Neuroimaging in the Emergency Patient Presenting with Seizure
Reassessment: Neuroimaging in the Emergency Patient Presenting with Seizure This evidence-based report provides clinicians with information to identify which seizure patients in the emergency department
More informationContents 1 Immunology for the Non-immunologist 2 Neurology for the Non-neurologist 3 Neuroimmunology for the Non-neuroimmunologist
1 Immunology for the Non-immunologist... 1 1 The Beginnings of Immunology... 1 2 The Components of the Healthy Immune Response... 2 2.1 White Blood Cells... 4 2.2 Molecules... 8 References... 13 2 Neurology
More informationEFAVIRENZ ASSOCIATED STEVENS-JOHNSON SYNDROME
EFAVIRENZ ASSOCIATED STEVENS-JOHNSON SYNDROME To the Editor: Persons with human immunodeficiency virus (HIV) infection are highly susceptible to adverse dermatological reactions to specific medications
More informationOI prophylaxis When to start, when to stop. Eva Raphael, MD MPH Family and community medicine, pgy-2 University of California, San Francisco
OI prophylaxis When to start, when to stop Eva Raphael, MD MPH Family and community medicine, pgy-2 University of California, San Francisco Learning Objectives o Recognize when to start OI prophylaxis
More informationThe importance of cohort collaborations for guiding clinical management of individuals with HIV infection
The importance of cohort collaborations for guiding clinical management of individuals with HIV infection Caroline Sabin Professor of Medical Statistics and Epidemiology Royal Free and University College
More informationWhen to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
More informationTreatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)
Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if
More informationmedical monitoring: clinical monitoring and laboratory tests
medical monitoring: clinical monitoring and laboratory tests Purpose of monitoring Check on the physical, psychological and emotional condition of the patient Detect other treatable conditions Identify
More informationDecreasing rates of Kaposi's sarcoma and non-hodgkin's lymphoma in the era of potent combination antiretroviral
CONCISE COMMUNICATION Decreasing rates of Kaposi's sarcoma and non-hodgkin's lymphoma in the era of potent combination antiretroviral therapy Andrew E. Grulich, Yueming Li, Ann M. McDonald, Patricia K.
More informationMild and Severe Adverse Effects of Antiretroviral Treatment
Mild and Severe Adverse Effects of Antiretroviral Treatment Gordon Dickinson, MD Professor of Medicine and Chief, Infectious Diseases, Miller School of Medicine, University of Miami Abacavir, available
More informationHIV and AIDS. Shan Nanji
HIV and AIDS Shan Nanji HIV 2 Description: Enveloped Positive Sense HIV 3 Structural Genes: Cleavage of gp160 leads to formation of ENV: Gp120: attachment to host CD4 T Cell Gp41: GAG (p24) Capsid protein
More information2. Clinical Manifestations (Pediatric HIV Infection)
Page 1 of 6 HOUSTON ROMANIA SOUTHERN AFRICA MEXICO HOME CONTACT Friday, July 25, 2003 Pediatric HIV Infection by Mark W. Kline, M.D. 1. Introduction 2. Clinical Manifestations 3. Diagnosis 2. Clinical
More informationThe Italian AIDS Epidemic Supports The Chemical AIDS Theory. Daniele Mandrioli
The Italian AIDS Epidemic Supports The Chemical AIDS Theory Daniele Mandrioli EPIDEMIOLOGY France Population: 65.073.482 AIDS Incidence: 16/million Germany Population: 82.438.000 AIDS Incidence: 4/million
More informationHIV Transmission HASPI Medical Biology Lab 20
HIV Transmission HASPI Medical Biology Lab 20 Background History of HIV/AIDS Acquired Immune Deficiency Syndrome (AIDS) was first seen in 1981 when large numbers of people with two rare diseases surfaced:
More informationImmune Reconstitution Inflammatory Syndrome - IRIS
Immune Reconstitution Inflammatory Syndrome - IRIS Douglas G. Fish, MD Head, Division of HIV Medicine Albany Medical College Cali, Colombia March 25, 2010 I-Tech: Thank you International Training and
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationDOWNLOAD PDF HIV-1 INFECTION OF THE CENTRAL NERVOUS SYSTEM
Chapter 1 : NIH Guide: HIV-1 INFECTION OF THE CENTRAL NERVOUS SYSTEM This Funding Opportunity Announcement (FOA) invites research grant applications focused on defining and understanding the pathogenic
More informationOriginal Article. Noparat Oniem, M.D., Somnuek Sungkanuparph, M.D.
Original Article Vol. 29 No. 1 Primary prophylaxis for cryptococcosis with fluconazole:- Oniem N & Sungkanuparph S. 5 Primary prophylaxis for cryptococcosis with fluconazole among HIV-infected patients
More informationProgressive Multifocal Leukoencephalopathy (PML)
Progressive Multifocal Leukoencephalopathy (PML) By Jamie Meier Introduction: Progressive multifocal leukoencephalopathy (PML) occurs when change in an individual s immune status triggers reactivation
More informationORIGINAL CONTRIBUTION. HIV-Associated Distal Sensory Polyneuropathy in the Era of Highly Active Antiretroviral Therapy
HIV-Associated Distal Sensory Polyneuropathy in the Era of Highly Active Antiretroviral Therapy The Manhattan HIV Brain Bank ORIGINAL CONTRIBUTION Susan Morgello, MD; Lydia Estanislao, MD; David Simpson,
More informationDOI: /hiv British HIV Association HIV Medicine (2013), 14, SHORT COMMUNICATION
DOI: 10.1111/hiv.12008 SHORT COMMUNICATION Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless
More informationManagement of Immune Reconstitution Inflammatory Syndrome (IRIS)
Management of Immune Reconstitution Inflammatory Syndrome (IRIS) Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the IRIS Guideline
More informationToxoplasmosis FACT SHEET. What is toxoplasmosis? Symptoms CONTACT US. Published 2016
Toxoplasmosis What is toxoplasmosis? Toxoplasmosis is an infection caused by the parasite Toxoplasma gondii (T. gondii). The parasite is transmitted to people through eating undercooked meat, especially
More informationPROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY
PROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY learn about the symptoms, diagnosing and treating this relatively rare brain condition associated with aids A PUBLICATION FROM Information, Inspiration and Advocacy
More informationDSM-5 and HAND. Diagnosis and Monitoring of HAND 10/6/2015. APA Institute on Psychiatric Services New York City
Diagnosis and Monitoring of HAND Karl Goodkin, MD, PhD Professor and Chair Department of Psychiatry and Behavioral Sciences East Tennessee State University Norman C. Moore, MD Director of Research, Professor
More informationClinical Information on West Nile Virus (WNV) Infection
Clinical Information on West Nile Virus (WNV) Infection Introduction In 1999, West Nile Virus (WNV), an Old World flavivirus, producing a spectrum of disease including severe meningoencephalitis, appeared
More informationYear 2002 Paper two: Questions supplied by Jo 1
Year 2002 Paper two: Questions supplied by Jo 1 Question 9 A 37 year old man with known human immunodeficiency virus (HIV) infection for 10 years presents with severe renal colic for which he has no prior
More informationAnti-viral drugs. Certain viruses multiply in the cytoplasm but others do in the nucleus Most multiplication take place before diagnosis is made
Anti-viral Drugs Viruses have no cell wall and made up of nucleic acid components Viruses containing envelope antigenic in nature Viruses are obligate intracellular parasite They do not have a metabolic
More informationHIV Update For the Internist
HIV Update For the Internist Disclosures I declare that I have received no incentives, financial or otherwise, from pharmaceutical or biomedical companies relevant to the content of this talk. As an Infectious
More informationThe prevalence and incidence of neurocognitive impairment in the HAART era
The prevalence and incidence of neurocognitive impairment in the HAART era Kevin R. Robertson a, Marlene Smurzynski b, Thomas D. Parsons a, Kunling Wu b, Ronald J. Bosch b, Julia Wu b, Justin C. McArthur
More informationNeurosarcoidosis. Walter Royal, III, MD Professor of Neurology and Anatomy and Neurobiology University of Maryland School of Medicine
Neurosarcoidosis Walter Royal, III, MD Professor of Neurology and Anatomy and Neurobiology University of Maryland School of Medicine Sarcoidosis A granulomatous disease of unknown etiology and no current
More informationThe following investigations are indicated for patients with intermediate or high-grade lymphoma in the setting of HIV infection:
HIV Lymphoma Dr. Matthew Cheung Updated August 2007 Updates: Hodgkin s Disease Introduction & Epidemiology Patients with HIV infection are at a significantly increased risk of developing certain types
More informationHIV - Life cycle. HIV Life Cyle
Human Immunodeficiency Virus Retrovirus - integrated into host genome ne single-strand RA 7,000 bases HIV1 > HIV2 > HIV0 Pathology Destruction of CD4+ T lymphocytes Loss of immune function pportunistic
More informationQuality of Life and Self-Reported Lower Extremity Function in Adults with HIV-related Distal Sensory Polyneuropathy
Quality of Life and Self-Reported Lower Extremity Function in Adults with HIV-related Distal Sensory Polyneuropathy Mary Lou Galantino, PT, PhD, MSCE Professor, Richard Stockton College of New Jersey MaryLou.Galantino@stockton.edu
More informationDiscontinuation of Secondary Prophylaxis against Disseminated Mycobacterium avium Complex Infection and Toxoplasmic Encephalitis
HIV/AIDS MAJOR ARTICLE Discontinuation of Secondary Prophylaxis against Disseminated Mycobacterium avium Complex Infection and Toxoplasmic Encephalitis Valérie Zeller, 1 Chantal Truffot, 2 Rachid Agher,
More information20 Years of Tears and Triumphs
20 Years of Tears and Triumphs A Clinical Research Nurse s Perspective on HIV/AIDS Bobi Keenan, RN, ACRN Clinical Research Nurse UC Irvine Dept. of Medicine/Infectious Diseases Objectives 1. Understand
More informationACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS
ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS Acquired immunodeficiency syndrome (AIDS ) is an infectious disease caused by a retrovirus, the human immunodeficiency virus(hiv). AIDS is
More informationMolecular studies of cerebrospinal fluid in human immunodeficiency virus type 1 associated opportunistic central nervous system diseases an update
Journal of NeuroVirology, 8(suppl. 2): 122 128, 2002 c 2002 Taylor & Francis ISSN 1355 0284/02 $12.00+.00 DOI: 10.1080/13550280290167957 Molecular studies of cerebrospinal fluid in human immunodeficiency
More informationORIGINAL CONTRIBUTION. Prediction of Incident Neurocognitive Impairment by Plasma HIV RNA and CD4 Levels Early After HIV Seroconversion
ORIGINAL CONTRIBUTION Prediction of Incident Neurocognitive Impairment by Plasma HIV RNA and CD4 Levels Early After HIV Seroconversion Thomas D. Marcotte, PhD; Reena Deutsch, PhD; J. Allen McCutchan, MD;
More informationSpectrums of opportunistic infections in HIV-infected patients at tertiary care hospital
Original Research Article Spectrums of opportunistic infections in HIV-infected patients at tertiary care hospital ShashiKumar H. Mundhra 1, Krati S. Mundhara 2, Nimisha Sunilbhai Trivedi 3, Yash Shah
More informationPeripheral neuropathy during stavudine-didanosine antiretroviral therapy
HIV Medicine (2001) 2, 92±96 ORIGINAL RESEARCH Ó 2001 British HIV Association Peripheral neuropathy during stavudine-didanosine antiretroviral therapy V Reliquet, 1 JM Mussini, 1 JM Chennebault, 2 A Lafeuillade
More informationChapter 22. Autoimmune and Immunodeficiency Diseases
Chapter 22 Autoimmune and Immunodeficiency Diseases Autoimmune Diseases Failures of self-tolerance Immune system fails to distinguish selfantigens from foreign antigens This results in the immune system
More informationAnti-viral drugs. Certain viruses multiply in the cytoplasm but others do in the nucleus Most multiplication take place before diagnosis is made
Anti-viral Drugs Viruses have no cell wall and made up of nucleic acid components Viruses containing envelope antigenic in nature Viruses are obligate intracellular parasite They do not have a metabolic
More informationClinical,Radiological and Monofilament study of HIV positive patients depending on the type of neurological symptoms manifestations.
Original article: Clinical,Radiological and Monofilament study of HIV positive patients depending on the type of neurological symptoms manifestations. 1Dr Anu N. Gaikwad, 2 Dr Satish Nirhale, 3 Dr Midhun
More informationTOXICITY, TOLERABILITY, AND ADHERENCE TO THERAPY
SAFETY AND TOLERABILITY OF CURRENTLY AVAILABLE ANTIRETROVIRAL AGENTS * Esteban Martinez, MD, PhD ABSTRACT Safety and tolerability are important factors to consider when instituting or modifying therapy
More informationDr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.
BHIVA AUTUMN CONFERENCE 2010 Including CHIVA Parallel Sessions Dr Alan Winston Imperial College Healthcare NHS Trust London 7-8 October 2010, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationPatterns and predictors of survival following an HIV/AIDS-related neurologic diagnosis
University of Iowa Iowa Research Online Theses and Dissertations 2012 Patterns and predictors of survival following an HIV/AIDS-related neurologic diagnosis Martha Lydia Carvour University of Iowa Copyright
More informationMedical monitoring: tests available at central hospitals
medial monitoring: tests available at central hospitals: 1 medical monitoring: tests available at central hospitals Medical monitoring: tests available at central hospitals medial monitoring: tests available
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More information